Amiloride (MK-870): Evidence-Driven Ion Transport Modulation

Executive Summary: Amiloride (MK-870) is a potent epithelial sodium channel (ENaC) inhibitor, validated in sodium channel research and ion transport assays (source: product_spec). It acts as a urokinase-type plasminogen activator receptor (uPAR) modulator, influencing cellular endocytosis and signaling (source: review). The compound is supplied as a stable solid (C6H8ClN7O; 229.63 g/mol) and must be stored at -20°C for optimal longevity (source: product_spec). Amiloride's applications span cystic fibrosis research, hypertension models, and advanced studies of receptor-mediated processes (source: internal_article). APExBIO guarantees consistent quality and documentation for research use.

Biological Rationale

ENaC channels mediate sodium absorption across epithelial tissues, regulating extracellular fluid volume and blood pressure. Aberrant ENaC activity is implicated in cystic fibrosis, hypertension, and airway diseases (source: internal_article). Urokinase-type plasminogen activator receptors (uPAR) are involved in cellular adhesion, migration, and signal transduction. Modulation of these targets with small molecules like Amiloride enables precise investigation of sodium flux and downstream signaling cascades (source: internal_article).

Mechanism of Action of Amiloride (MK-870)

Amiloride (MK-870) blocks ENaC channels by directly binding to the extracellular pore, preventing sodium influx and reducing transmembrane potential (source: product_spec). It also inhibits uPAR-mediated endocytosis, impacting cellular uptake and signal propagation (source: internal_article). This dual action distinguishes Amiloride from standard sodium channel blockers, supporting investigations into both transport and signaling phenomena. Its specificity has been confirmed in comparative studies against other ENaC inhibitors (source: internal_article).

Evidence & Benchmarks

• Amiloride exhibits half-maximal inhibitory concentration (IC₅₀) values for ENaC of 0.1–1 μM in epithelial cell assays (source: product_spec).
• In cystic fibrosis airway models, Amiloride reduces sodium absorption and enhances mucociliary clearance compared to vehicle (source: internal_article).
• Amiloride reversibly inhibits uPAR-mediated cellular endocytosis at concentrations above 10 μM (source: internal_article).
• Long-term storage at -20°C preserves Amiloride's bioactivity for at least 12 months as a solid (source: product_spec).
• Amiloride solutions lose potency within 48 hours at room temperature (source: workflow_recommendation).
• Its selectivity for ENaC over other sodium channels is at least 10-fold in direct patch-clamp comparisons (source: internal_article).

For an in-depth mechanistic review, see Amiloride (MK-870): A Gateway to Next-Level Cellular Modulation, which expands on Amiloride's role in cellular endocytosis modulation. This article extends prior summaries by providing protocol parameters and clarifying cross-domain boundaries.

Applications, Limits & Misconceptions

Amiloride (MK-870) is widely used for:

• Sodium channel research in airway, renal, and colonic epithelia.
• Dissecting the role of ENaC in cystic fibrosis pathogenesis and therapy development.
• Investigating hypertension mechanisms via renal sodium handling.
• Studying uPAR involvement in cellular uptake and migration.

However, its specificity is limited in some cell types, and high concentrations may affect other ion channels. Amiloride does not block voltage-gated sodium channels or calcium channels at research-relevant doses (source: internal_article).

Common Pitfalls or Misconceptions

• Assuming Amiloride inhibits all sodium channels—It is selective for ENaC and not voltage-gated sodium channels.
• Expecting long-term solution stability—Amiloride solutions degrade rapidly and should be used promptly (source: workflow_recommendation).
• Using Amiloride in systems with high serum protein, which can bind and sequester the compound, reducing efficacy.
• Misapplying Amiloride in calcium channel assays, where it shows no activity at standard concentrations.
• Overlooking uPAR-independent effects at concentrations above 100 μM, where off-target effects may emerge.

Workflow Integration & Parameters

Protocol Parameters

• assay: ENaC inhibition | value_with_unit: 0.1–1 μM IC₅₀ | applicability: airway and renal epithelia | rationale: Maximizes ENaC blockade with minimal off-target effects | source_type: product_spec
• assay: uPAR-mediated endocytosis | value_with_unit: 10–20 μM | applicability: cell migration and signaling studies | rationale: Effective uPAR inhibition in migration assays | source_type: internal_article
• assay: Storage (solid) | value_with_unit: -20°C | applicability: all research | rationale: Preserves compound integrity for ≥12 months | source_type: product_spec
• assay: Solution use window | value_with_unit: <48 hours at RT | applicability: all solution-based protocols | rationale: Prevents degradation and potency loss | source_type: workflow_recommendation
• assay: Shipping conditions | value_with_unit: blue ice | applicability: small-molecule delivery | rationale: Maintains stability during transit | source_type: product_spec

For ordering and documentation, see the Amiloride (MK-870) product page from APExBIO.

Conclusion & Outlook

Amiloride (MK-870) remains a foundational tool for sodium channel research, cellular endocytosis modulation, and disease modeling. Its validated potency, clear mechanistic profile, and robust storage guidelines support reproducible results across diverse research settings (source: product_spec). Ongoing advances in nanomedicine and immunomodulation, such as ER-targeted delivery systems, reinforce the importance of precise ion transport modulation as a platform for translational discovery (source: benchmark_DOI).

For a strategic perspective on Amiloride's evolving research applications, Amiloride (MK-870): Mechanistic and Strategic Paradigms for Next-Gen Research provides a comparative framework. This current article updates the field by addressing workflow integration and debunking persistent misconceptions.